Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Videos

Low molecular weight heparins. An objective overview.

D Hoppensteadt1, J M Walenga, J Fareed

  • 1Department of Pathology, Loyola University Medical Center, Maywood, Illinois.

Drugs & Aging
|September 1, 1992
PubMed
Summary

Low molecular weight heparins (LMWHs) offer superior prophylactic antithrombotic results and better tolerability compared to traditional drugs. Each LMWH exhibits distinct efficacy, with new agents under development for broader clinical applications.

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Regional and Systemic Prothrombotic Biomarkers in Varicose Vein Patients and Healthy Controls.

Journal of vascular surgery. Venous and lymphatic disorders·2016
Same author

Blood Sampled Directly from Varicose Veins Reveals Activation of Inflammatory Processes.

Journal of vascular surgery. Venous and lymphatic disorders·2016
Same author

Do blood constituents in varicose veins differ from the systemic blood constituents?

European journal of vascular and endovascular surgery : the official journal of the European Society for Vascular Surgery·2015
Same author

Elevated endocan levels and its association with clinical severity in Stevens-Johnson Syndrome and toxic epidermal necrolysis.

International angiology : a journal of the International Union of Angiology·2014
Same author

Pharmacological profile of sulodexide.

International angiology : a journal of the International Union of Angiology·2014
Same author

Medical management of patients with peripheral arterial disease.

International angiology : a journal of the International Union of Angiology·2014

Area of Science:

  • Pharmacology
  • Hematology
  • Thrombosis Management

Background:

  • Low molecular weight heparins (LMWHs) represent a significant advancement in managing thrombotic disorders.
  • Ten LMWH formulations are currently approved for clinical use, with increasing evaluation in countries like the US.

Purpose of the Study:

  • To review the clinical utility and distinct characteristics of available low molecular weight heparins.
  • To highlight the comparative efficacy and tolerability of LMWHs against other antithrombotic agents.

Main Methods:

  • Review of well-designed clinical trials evaluating LMWHs for various indications.
  • Comparison of experimental and clinical data on prophylactic antithrombotic efficacy and tolerability.

Main Results:

Related Experiment Videos

  • LMWHs demonstrate consistently impressive clinical results for prophylaxis, surpassing traditional antithrombotic drugs like heparin, warfarin, and aspirin.
  • LMWHs exhibit a more favorable tolerability profile compared to other antithrombotic agents.
  • The prophylactic antithrombotic efficacy of each LMWH is unique to the specific drug.

Conclusions:

  • LMWHs have revolutionized thrombotic disorder management, offering superior efficacy and tolerability.
  • Ongoing development of approximately 14 new LMWH agents suggests continued innovation in this field.
  • Future applications for LMWHs are expected to expand beyond prophylaxis to therapeutic interventions, necessitating adherence to regulatory guidelines and product-specific trials.